Silexion Therapeutics Corp
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage biotechnology company focused on RNA-interference therapeutics for KRAS-driven cancers. Its lead program, SIL204, is being developed as a locally administered siRNA treatment for locally advanced pancreatic cancer, alongside a broader pipeline of oncology product candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaSIL204 and related siRNA-based oncology treatments targeting KRAS-driven tumors.
Discovery, toxicology, and translational work supporting future product candidates.
Human trial planning and execution for oncology drug candidates.
Asiakkaat
Silexion does not yet sell commercial products; its near-term counterparties are clinical investigators, trial sites, regulators, and research partners involved in advancing SIL204. If approved, its eventual customers would be hospitals, oncologists, and healthcare systems treating pancreatic cancer and other KRAS-driven solid tumors.
Trial sites, investigators, CROs, and research collaborators that support SIL204 testing and data generation.
U.S., EU, and other regulators that review toxicology, clinical, and approval submissions.
Hospitals, oncologists, and cancer centers that could use approved KRAS-targeted therapies.
Strategia
Silexion’s strategy is centered on advancing SIL204 through pre-clinical work, toxicology, and clinical trials while building the data package needed for regulatory approval. It also seeks to expand its pipeline, protect intellectual property, and secure the funding required to support long development timelines in oncology.
Clinical data are required to validate the therapeutic concept and support future approval.
Regulatory milestones and patent protection are central to value creation in biotech.
The company needs capital to sustain R&D and diversify beyond a single lead asset.
Maantiede
The company is organized as a Cayman Islands holding company with operations primarily conducted through Silexion, which has historical financing ties to Israel. Its commercial geography is not yet established because it has not generated product revenue, but its development plans reference the U.S., EU, and other territories for future regulatory and market access.
Riskit
Silexion is exposed to the core risks of clinical-stage biotechnology: development failure, regulatory delay, and the possibility that approved products never achieve commercial adoption. Its business also depends on continued external financing, because it has not yet generated product revenue and must fund long-duration R&D and trial activity.
SIL204 must generate convincing safety and efficacy data before approval is possible.
Kohdistuu: Lead program SIL204
The company has not generated revenue and expects substantial funding needs.
Kohdistuu: R&D and trial funding
Approval depends on successful toxicology, clinical, and submission outcomes across jurisdictions.
Value is heavily tied to one lead candidate and a narrow oncology platform.
Kohdistuu: SIL204 and KRAS-focused programs
Equity and warrant financings can dilute holders and affect share price.
Kohdistuu: Public-company financing
Kirjanpito
Harkinnanvaraiset erätNotes issued in the business combination are measured at fair value using management forecasts and credit assumptions.
Vaikutus: Can create non-cash gains or losses and affect liabilities
Discount rates, credit spreads, and conversion timing require judgment.
Vaikutus: Affects balance sheet values and earnings volatility
Trial, subcontractor, and payroll spending can shift materially by period.
Vaikutus: Drives operating loss comparability across quarters
Equity-linked instruments can create non-cash expense and dilution effects.
Vaikutus: Affects reported earnings and per-share metrics
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
DiaMedica Therapeutics Inc.
DMAC · Pharmaceutical Preparations
Päivitetty: 24.9.2026